The Development of Chinese Herbal Formulae for Non-severe COVID-19 Based on Artificial Intelligence Technology and Investigation of Its Action Mechanisms

HUANG Wenting; QIAO Liansheng; YAN Di; LIU Tengwen; CAO Hongmei; GUO Hongyan; ZHANG Zhi; CHENG Jing; XIE Lan; LIU Qingquan

doi:10.13288/j.11-2166/r.2024.01.018

您当前的位置：

首页 >

文章列表页 >

The Development of Chinese Herbal Formulae for Non-severe COVID-19 Based on Artificial Intelligence Technology and Investigation of Its Action Mechanisms

更新时间：2024-01-09

- The Development of Chinese Herbal Formulae for Non-severe COVID-19 Based on Artificial Intelligence Technology and Investigation of Its Action Mechanisms
- Journal of Traditional Chinese Medicine Vol. 65, Issue 1, Pages: 103-112(2024)
- 作者机构：
  
  1.清华大学医学院医学系统生物学研究中心，北京市海淀区双清路30号，100084
  2.生物芯片北京国家工程研究中心
  3.成都中医药大学基础医学院
  4.北京博奥晶方生物科技有限公司
  5.首都医科大学附属北京中医医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2024.01.018
  CLC：
- Received：28 August 2023，
  
  Revised：2023-11-01，
  
  Published：02 January 2024
- 稿件说明：
移动端阅览
黄文婷,乔连生,闫迪等.基于人工智能技术的治疗非重症新型冠状病毒感染中药方剂研发及其作用机制研究[J].中医杂志,2024,65(01):103-112.

HUANG Wenting,QIAO Liansheng,YAN Di,et al.The Development of Chinese Herbal Formulae for Non-severe COVID-19 Based on Artificial Intelligence Technology and Investigation of Its Action Mechanisms[J].Journal of Traditional Chinese Medicine,2024,65(01):103-112.
黄文婷,乔连生,闫迪等.基于人工智能技术的治疗非重症新型冠状病毒感染中药方剂研发及其作用机制研究[J].中医杂志,2024,65(01):103-112. DOI： 10.13288/j.11-2166/r.2024.01.018.

HUANG Wenting,QIAO Liansheng,YAN Di,et al.The Development of Chinese Herbal Formulae for Non-severe COVID-19 Based on Artificial Intelligence Technology and Investigation of Its Action Mechanisms[J].Journal of Traditional Chinese Medicine,2024,65(01):103-112. DOI： 10.13288/j.11-2166/r.2024.01.018.

摘要

目的

研发治疗非重症新型冠状病毒感染（COVID-19）的中药方剂并验证其抗炎作用机制。

方法

基于COVID-19患者支气管肺泡灌洗液中巨噬细胞的表达谱和新型冠状病毒（SARS-CoV-2）体外感染的肺上皮细胞表达谱分别确定了COVID-19在这两类细胞中失调的信号通路。通过文献收集临床治疗非重症COVID-19的中药方剂102首，基于特征信号通路评价102首方剂在肺上皮细胞和巨噬细胞中的通路逆转率，并根据中医理论确定“基础方”。通过临床常用方剂总结得到治疗非重症COVID-19的常用药，结合《中华人民共和国药典》中药筛选结果得到COVID-19中药方剂研发的“药物池”。通过靶向转录组获得每味药物对信号通路的调控作用，以逆转COVID-19失调的信号通路为目标展开计算，基于中药智能组方方法采用穷举法和平行运算进行组方得到若干个候选复方，参考中医专业经验最终得出治疗非重症COVID-19的守正创新方。采用RT-qPCR法检测该组方醇提物对脂多糖（LPS）处理的RAW264.7细胞中白细胞介素1b（IL1b）、C-X-C基序趋化因子配体2（Cxcl2）、C-X-C基序趋化因子配体10（Cxcl10）、C-C基序趋化因子配体2（Ccl2）、一氧化氮合成酶2（Nos2）和前列腺素内过氧化物合成酶2（Ptgs2）mRNA的表达，对抗炎效果进行验证。

结果

在巨噬细胞和肺上皮细胞中，确定了COVID-19相关的各34条失调信号通路。基于失调信号通路和中药靶向转录组，对临床治疗非重症COVID-19的102首中药复方的功效进行评估，结果显示银翘散合平胃散在巨噬细胞及肺上皮细胞上的通路逆转率分别为91.18%和100%，效果最佳；且该复方具有疏风清热、解毒化湿的功效，符合COVID-19风热夹湿的病机，故选用银翘散合平胃散作为守正创新方研发的基础方。利用中药智能组方方法结合中医专业经验对银翘散合平胃散进行加减化裁，得到守正创新方翘蒡术皮饮。该方逆转了巨噬细胞和肺上皮细胞上COVID-19相关全部失调信号通路，逆转率均为100%。翘蒡术皮饮中的君药连翘、豨莶草和牛蒡子可下调多条与病毒感染、免疫及损伤增值相关的信号通路。RT-qPCR结果表明，与模型组比较，翘蒡术皮饮组下调了LPS诱导RAW264.7细胞中的IL1b、Tnf、Cxcl2、Cxcl10、Ccl2、Nos2和Ptgs2 mRNA表达（

＜0.05或

＜0.01）。

结论

基于靶向转录组、中医专业经验和人工智能研发得到治疗非重症COVID-19的翘蒡术皮饮，该方剂的乙醇提取物在细胞炎症模型上能够抑制多种促炎基因的表达。

Abstract

Objective

To develop traditional Chinese medicine （TCM） formulae for the treatment of nonsevere coronavirus disease 2019 （COVID-19） and to explore its anti-inflammatory mechanism.

Methods

The dysregulated signaling pathways were determined in macrophages from bronchoalveolar lavage fluid of COVID-19 patients and in lung epithelial cells infected with SARS-CoV-2

in vitro

based on transcriptome analysis

A total of 102 TCM formulae for the clinical treatment of nonsevere COVID-19 were collected through literature. The pathway-reversing rates of these formulae in macrophages and lung epithelial cells were evaluated based on signature signaling pathways， and the basic formula was determined in conjunction with TCM theory. The commonly used Chinese materia medica for nonsevere COVID-19 were summarized from the 102 TCM formulae as abovementioned. And together with the screening results from the

Pharmacopoeia of the People's Republic of China

， a “Chinese materia medica pool” was esta-blished for the development of TCM formulae for COVID-19. The regulatory effects of each herb on signaling pathways were obtained based on targeted transcriptome analysis. Oriented at reversing dysregulated signaling pathways of COVID-19， the calculation was carried out， and the artificial intelligent methods for compositing formulae， that are exhaustive method and parallel computing， were used to obtain candidate compound formulas. Finally， with reference to professional experience， an innovative formula for the treatment of nonsevere COVID-19 was developed. The ethanol extract of the formula was evaluated for its anti-inflammatory effects by detecting the mRNA expression of interleukin 1b （

Il1b

）， C-X-C motif chemokine ligand 2 （

Cxcl2

）， C-X-C motif chemokine ligand 10 （

Cxcl10

）， C-C motif chemokine ligand 2 （

Ccl2

）， nitric oxide synthase 2 （

Nos2

）， and prostaglandin-endoperoxide synthase 2 （

Ptgs2

） using reverse transcription-quantitative polymerase chain reaction （RT-qPCR） in RAW264.7 cells treated with lipopolysaccharide （LPS）.

Results

In macrophages and lung epithelial cells， 34 dysregulated signaling pathways associated with COVID-19 were identified respectively. The effects of the 102 formulae for clinical treatment of nonsevere COVID-19 were evaluated based on the dysregulated signaling pathways and targeted transcriptome， and the result showed that

Yinqiao Powder and Pingwei Powder

（银翘散合平胃散， YQPWP） ranked first， reversing 91.18% of the dysregulated signaling pathways in macrophages and 100% of the dysregulated signaling pathways in lung epithelial cells. Additionally， YQPWP had the function of scattering wind and clearing heat， resolving toxins and removing dampness in accordance with the pathogenesis of wind-heat with dampness in COVID-19. It was selected as the basic formula， and was further modified and optimized to develop an innovative fomula

Qiaobang Zhupi Yin

（翘蒡术皮饮， QBZPY） based on expert experience and artificial intelligence in composing formulae. QBZPY can reverse all the dysregulated signaling pathways associated with COVID-19 in macrophages and lung epithelial cells， with the reversing rates of 100%. The chief medicinal of QBZPY， including Lianqiao （

Fructus Forsythiae

）， Xixiancao （

Herba Siegesbeckiae

） and Niubangzi （

Fructus Arctii

）， can down-regulate multiple signaling pathways related with virus infection， immune response， and epithelial damage. RT-qPCR results indicated that compared with the model group， the QBZPY group down-regulated the mRNA expression of

Il1b

， tumor necrosis factor （Tnf），

Cxcl2

，

Cxcl10

，

Ccl2

，

Nos2

and

Ptgs2

induced by LPS in RAW264.7 cells （

＜0.05 or

＜0.01）.

Conclusion

Based on targeted transcriptome analysis， expert experience in TCM and artificial intelligence， QBZPY has been developed for the treatment of nonsevere COVID-19. The ethanol extract of QBZPY has been found to inhibit mRNA expression of several pro-inflammatory genes in a cellular inflammation model.

关键词

Keywords

references

GANDHI RT ， LYNCH JB ， DELRIO C . Mild or moderate COVID-19 ［J］. N Engl J Med ， 2020 ， 383 （ 18 ）： 1757 - 1766 .

YU W ， GUO Y ， ZHANG S ， et al . Proportion of asympto-matic infection and nonsevere disease caused by SARS-CoV-2 Omicron variant： a systematic review and analysis ［J］. J Med Virol ， 2022 ， 94 （ 12 ）： 5790 - 5801 .

HUANG K ， ZHANG P ， ZHANG Z ， et al . Traditional Chinese medicine （TCM） in the treatment of viral infections： efficacies and mechanisms ［J］. Pharmacol Ther ， 2021 ， 225 ： 107843 . doi： 10.1016/j.pharmthera. 2021. 107843 http://dx.doi.org/10.1016/j.pharmthera.2021.107843 .

栾鑫，黄敏，柯博文，等 . 源于临床有效中药活性成分的创新药物研发策略与挑战［J］. 中国中药杂志， 2023 ， 48 （ 7 ）： 1705 - 1710 .

SCHULTZE JL ， ASCHENBRENNER AC . COVID-19 and the human innate immune system ［J］. Cell ， 2021 ， 184 （ 7 ）： 1671 - 1692 .

FAJGENBAUM DC ， JUNE CH . Cytokine storm ［J］. N Engl J Med ， 2020 ， 383 （ 23 ）： 2255 - 2273 .

LIAO M ， LIU Y ， YUAN J ， et al . Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 ［J］. Nat Med ， 2020 ， 26 （ 6 ）： 842 - 844 .

SUBRAMANIAN A ， TAMAYO P ， MOOTHA VK ， et al . Gene set enrichment analysis： a knowledge-based approach for interpreting genome-wide expression profiles ［J］. Proc Natl Acad Sci USA ， 2005 ， 102 （ 43 ）： 15545 - 15550 .

KANEHISA M ， FURUMICHI M ， SATO Y ， et al . KEGG： integrating viruses and cellular organisms ［J］. Nucleic Acids Res ， 2020 ， 49 （ D1 ）： D545 - D551 .

BURGOYNE RA ， FISHER AJ ， BORTHWICK LA . The role of epithelial damage in the pulmonary immune response ［J］. Cells ， 2021 ， 10 （ 10 ）： 2763 .

JONE AE ， JOSEPH C ， JENKINS G ， et al . COVID-19 and pulmonary fibrosis： a potential role for lung epithelial cells and fibroblasts ［J］. Immunol Rev ， 2021 ， 302 （ 1 ）： 228 - 240 .

BRIDGES JP ， VLADAR EK ， HUANG H ， et al . Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19 ［J］. Thorax ， 2022 ， 77 （ 2 ）： 203 - 209 .

BLANCO-MELO D ， NILSSON-PAYANT BE ， LIU W ， et al . Imbalanced host response to SARS-CoV-2 drives development of COVID-19 ［J］. Cell ， 2020 ， 181 （ 5 ）： 1036 - 1045 .

王琦，谷晓红，刘清泉 . 新型冠状病毒肺炎中医诊疗手册［M］. 北京：中国中医药出版社， 2020 ： 7-12，27-28 .

国家药典委员会 . 中华人民共和国药典：一部［M］. 北京：中国医药科技出版社， 2020 .

QIAO L ， HUANG W ， ZHANG X ， et al . Evaluation of the immunomodulatory effects of anti-COVID-19 TCM formulae by multiple virus-related pathways ［J］. Signal Transduct Target Ther ， 2021 ， 6 （ 1 ）： 577 - 579 .

DAI Y ， QIANG W ， GUI Y ， et al . A large-scale transcriptional study reveals inhibition of COVID-19 related cytokine storm by traditional Chinese medicines ［J］. Sci Bull ， 2021 ， 66 （ 9 ）： 884 - 888 .

乔连生，李军，谢兰，等 . 基于靶向转录组、专家经验和人工智能研发守正创新中药的路径探索：以治疗慢性心力衰竭的中药新药研发为例［J］. 中医杂志， 2023 ， 64 （ 3 ）： 217 - 224 .

刘玉超，王玉光，郭建，等 . 刘清泉辨治新型冠状病毒感染疫病思路与常用方药探析［J］. 现代中医临床， 2023 ， 30 （ 4 ）： 6 - 11 .

陈丽名，刘绍永，张林，等 . 关于经方与当代处方的全方总药量比较［J］. 中华中医药杂志， 2015 ， 30 （ 3 ）： 735 - 738 .

FENG J ， YANG J ， CHANG Y ， et al . Caffeine-free hawk tea lowers cholesterol by reducing free cholesterol uptake and the production of very-low-density lipoprotein ［J］. Commun Biol ， 2019 ， 2 ： 173 .

BOURGONJE AR ， ABDULLE AE ， TIMENS W ， et al . Angiotensin‐converting enzyme 2 （ACE2）， SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 （COVID‐19）［J］. J Pathol ， 2020 ， 251 （ 3 ）： 228 - 248 .

MERAD M ， MARTIN JC . Pathological inflammation in patients with COVID-19： a key role for monocytes and macrophages ［J］. Nat Rev Immunol ， 2020 ， 20 （ 6 ）： 355 - 362 .

WANG J ， LUO L ， ZHAO X ， et al . Forsythiae fructuse extracts alleviates LPS-induced acute lung injury in mice by regulating PPAR-γ/RXR-α in lungs and colons ［J］. J Ethnopharmacol ， 2022 ， 293 ： 115322 . doi： 10.1016/j.jep. 2022.115322 http://dx.doi.org/10.1016/j.jep.2022.115322 .

ZHOU M ， TANG Y ， LIAO L ， et al . Phillygenin inhibited LPS-induced RAW 264.7 cell inflammation by NF-κB pathway ［J］. Eur J Pharmacol ， 2021 ， 899 ： 174043 . doi： 10.1016/j.ejphar.2021.174043 http://dx.doi.org/10.1016/j.ejphar.2021.174043 .

徐丽伟，徐帅，王菁，等 . 豨莶草药理作用研究进展［J］. 长春中医药大学学报， 2021 ， 37 （ 3 ）： 704 - 708 .

GUO H ， ZHANG Y ， CHENG BC ， et al . An ethanolic extract of the aerial part of Siegesbeckia orientalis L. inhibits the production of inflammatory mediators regulated by AP-1， NF-κB and IRF3 in LPS-stimulated RAW 264.7 cells ［J］. Biosci Trends ， 2018 ， 12 （ 3 ）： 330 - 337 .

聂发龙，赵显芳，朱紫陌，等 . 牛蒡子苷减轻脂多糖诱导人鼻咽上皮细胞炎症损伤的作用［J］. 中国药房， 2022 ， 33 （ 12 ）： 1436 - 1441 .

HUANG Y ， BAI C ， HE F ， et al . Review on the potential action mechanisms of Chinese medicines in treating coronavirus disease 2019 （COVID-19）［J］. Pharmacol Res ， 2020 ， 158 ： 104939 . doi： 10.1016/j.phrs.2020.104939 http://dx.doi.org/10.1016/j.phrs.2020.104939 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The Exploration of a New Approach for Developing Innovative Chinese Herbal Formulae by Combining Targeted Transcriptome， Expert Experience and Artificial Intelligence： Taking the Development of Anti-chronic Heart Failure Innovative Formula as an Example

An AI-Driven Research Pathway for Upholding Fundamental Principles and Breaking New Ground of Traditional Chinese Medicine Under the Guidance of Complexity Science

Construction and Clinical Validation of a Deep Learning-Based Automatic Measurement Model for Palmar Tilt and Radial Inclination in Distal Radius Fractures

Construction and Application of a Real-World Cohort of Community-Acquired Pneumonia Based on a Multimodal Large-Scale Traditional Chinese Medicine Big Data Platform

The Current Issues and Thoughts on the Empowerment of Famous Doctors' Experience Inheritance by Artificial Intelligence

Related Author

LI Jun

XIE Lan

ZHANG Zhenpeng

CHANG Yujun

GUO Hongyan

XIE Zicong

WANG Jie

CHENG Jing

Related Institution

Guang'anmen Hospital，China Academy of Chinese Medical Sciences

Beijing CapitalBio Pharma Technology Co，Ltd.

Guang 'anmen Hospital，China Academy of Chinese Medical Sciences

Tsinghua University

School of Intelligent Science and Technology，University of Science and Technology Beijing

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰